A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Conditions
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Waldenstrom Macroglobulinemia (WM) · Mantle Cell Lymphoma (MCL) · Marginal Zone Lymphoma (MZL) · Follicular Lymphoma (FL) · Diffuse Large B-cell Lymphoma (DLBCL) · Primary Central Nervous System Lymphoma (PCNSL)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope, Duarte, California, United States
University of California Irvine, Orange, California, United States
University of California San Francisco Medical Center, San Francisco, California, United States
Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver, Colorado, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
OSU Wexner Medical Center, Columbus, Ohio, United States
Tennessee Oncology, Nashville, Tennessee, United States
Baylor University Medical Center, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Swedish Cancer Institute, Seattle, Washington, United States
Study leads
Study Director
Nurix Therapeutics, Inc.